Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,284 across all filing types
Latest filing 2024-11-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
第五届监事会第十五次（临时）会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Tianjin Ruipu Biotechnology Co., Ltd. regarding the approval of a related party transaction involving the acquisition of a 15% equity stake in another company. It includes details about the meeting, attendance, voting results, and compliance with laws and company articles. The document references a more detailed announcement available on the Shenzhen Stock Exchange and CNINFO websites. The content is a formal meeting resolution announcement rather than a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a regulatory certification or voting result announcement. It fits best under Regulatory Filings (RNS) as a general regulatory announcement about corporate governance and related party transactions.
2024-11-07 Chinese
第五届董事会第十九次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution by Tianjin Ruipu Biotechnology Co., Ltd. It details the approval of a transaction involving the acquisition of partial equity in another company. The document includes information about the meeting date, attendance, voting results, and references to related disclosures on official websites. There is no detailed financial report or comprehensive analysis, but rather a formal announcement of a board decision. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors or senior management.
2024-11-07 Chinese
股份回购报告书
Transaction in Own Shares Classification · 95% confidence The document is titled as a "股份回购报告书" which translates to "Share Repurchase Report" or "Share Buyback Report." It details the company's plan to repurchase its own shares using bank loans and own funds, specifying the amount, price limits, purpose (for equity incentives or employee stock ownership plans), and the timeline. It includes detailed information about the repurchase plan, authorization, risk disclosures, and regulatory compliance references. The document is not a brief announcement but a comprehensive report on the share repurchase plan. This matches the definition of "Transaction in Own Shares (POS)" which covers reports of the company buying back or selling its own shares. The document is about the repurchase plan itself, not just an announcement of a report or a brief notice. Therefore, the correct classification is POS with high confidence.
2024-11-06 Chinese
关于回购股份事项前十名股东及前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from Tianjin Ruipu Biotechnology Co., Ltd. regarding the shareholding situation of the top ten shareholders and top ten unrestricted shareholders prior to a share repurchase plan. It references a board meeting approving a share repurchase plan and details the shareholding percentages of major shareholders as of a specific date. The document does not contain financial statements or detailed financial analysis but focuses on shareholding data related to a share repurchase. This fits the description of a Transaction in Own Shares (POS) filing, which reports on company buybacks or sales of its own shares. The document length is short (1556 characters) and is not merely an announcement of a report but contains substantive shareholding data relevant to the repurchase. Therefore, the correct classification is POS with high confidence.
2024-11-06 Chinese
关于回购公司股份方案暨与金融机构签订股票回购借款合同的公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from Tianjin Ruipu Biotechnology Co., Ltd. regarding a share repurchase plan, including the purpose, amount, price range, funding sources, implementation period, and related risks. It also mentions the signing of a stock repurchase loan contract with a financial institution. The content focuses on the company's plan to buy back its own shares for employee stock ownership or incentive plans, with detailed financial and procedural information. There is no indication that this is a full financial report, earnings release, or regulatory certification. The document is not a report publication announcement but a substantive announcement about share repurchase activities. Therefore, the document fits the category of Transaction in Own Shares (POS). The document length (6968 characters) supports it being a full announcement rather than a brief notice.
2024-11-04 Chinese
第五届董事会第十八次（临时）会议决议公告
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement of a board meeting resolution regarding a share repurchase plan. It details the purpose, conditions, price range, quantity, funding source, implementation period, and authorization for the share buyback. The text includes voting results and references to regulatory compliance but does not contain financial statements or performance data. The document length is about 3300 characters, which is relatively short and focused on the announcement of the share repurchase plan rather than the execution or financial results of the repurchase. Therefore, this is not a full financial report or management discussion but an official announcement of a share repurchase plan, fitting the category of Transaction in Own Shares (POS).
2024-11-04 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.